ATE513850T1 - Verfahren zur aufreinigung von apo-2-ligand/trail unter anwendung von kristallisation im kalten - Google Patents

Verfahren zur aufreinigung von apo-2-ligand/trail unter anwendung von kristallisation im kalten

Info

Publication number
ATE513850T1
ATE513850T1 AT06759514T AT06759514T ATE513850T1 AT E513850 T1 ATE513850 T1 AT E513850T1 AT 06759514 T AT06759514 T AT 06759514T AT 06759514 T AT06759514 T AT 06759514T AT E513850 T1 ATE513850 T1 AT E513850T1
Authority
AT
Austria
Prior art keywords
trail
crystalization
ligand
cold
purifying apo
Prior art date
Application number
AT06759514T
Other languages
English (en)
Inventor
Heather Flores
Tanya Lin
Timothy Matthews
Roger Pai
Zahra Shahrokh
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE513850T1 publication Critical patent/ATE513850T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
AT06759514T 2005-05-24 2006-05-10 Verfahren zur aufreinigung von apo-2-ligand/trail unter anwendung von kristallisation im kalten ATE513850T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/136,842 US7741285B2 (en) 2001-11-13 2005-05-24 APO-2 ligand/trail formulations
PCT/US2006/018137 WO2006127284A2 (en) 2005-05-24 2006-05-10 Method of purifying apo-2 ligand/trail using crystallisation in the cold

Publications (1)

Publication Number Publication Date
ATE513850T1 true ATE513850T1 (de) 2011-07-15

Family

ID=37150024

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06759514T ATE513850T1 (de) 2005-05-24 2006-05-10 Verfahren zur aufreinigung von apo-2-ligand/trail unter anwendung von kristallisation im kalten

Country Status (16)

Country Link
US (2) US7741285B2 (de)
EP (1) EP1888624B1 (de)
JP (2) JP2008542269A (de)
KR (1) KR101283802B1 (de)
CN (1) CN101228183B (de)
AT (1) ATE513850T1 (de)
AU (1) AU2006249494B2 (de)
BR (1) BRPI0611368A2 (de)
CA (1) CA2609188C (de)
ES (1) ES2368445T3 (de)
IL (1) IL187396A (de)
MX (1) MX2007014728A (de)
NZ (1) NZ563518A (de)
RU (1) RU2435781C2 (de)
WO (1) WO2006127284A2 (de)
ZA (1) ZA200710325B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466054C (en) * 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
EP4328305A3 (de) 2009-12-18 2024-08-14 CSL Ltd. Verfahren zur reinigung von polypeptiden
SMT202500087T1 (it) 2015-01-30 2025-03-12 Oncoceutics Inc Derivati di 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-esaidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-one, loro sali e loro uso in terapia
JP6699085B2 (ja) * 2015-03-25 2020-05-27 東ソー株式会社 Fc結合性タンパク質の精製方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010908D1 (de) * 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
CA2225378C (en) * 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
US6284236B1 (en) * 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
NZ334309A (en) 1996-10-25 2000-08-25 Human Genome Sciences Inc Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
NZ508381A (en) 1997-03-17 2002-09-27 Human Genome Sciences Inc Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
WO1998046643A1 (en) 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
EA003636B1 (ru) 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
PT981618E (pt) 1997-05-15 2007-11-23 Genentech Inc ''anticorpo anti-apo-2''
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
JP2001514888A (ja) 1997-08-15 2001-09-18 アイドゥン ファーマシューティカルズ, インコーポレイテッド Trailレセプター、これをコードする核酸、およびその使用方法
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
CA2318029C (en) 1998-01-15 2009-05-19 Genentech, Inc. Apo-2 ligand
PT1064027E (pt) 1998-03-27 2008-09-29 Genentech Inc Sinergismo de ligando de apo-2 e anticorpo anti-her-2
ATE330972T1 (de) 1999-06-09 2006-07-15 Genentech Inc Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
EP1194555B1 (de) 1999-06-28 2012-09-26 Genentech, Inc. Verfahren zur herstellung von apo-2 ligand unter gebrauch von divalenten metallionen
WO2002009755A2 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
CA2466054C (en) * 2001-11-13 2012-01-03 Genentech, Inc. Apo-2 ligand/trail formulations
RU2379056C2 (ru) * 2002-11-27 2010-01-20 Айрм Ллс Способы и композиции для индукции апоптоза раковых клеток
CN1473843A (zh) * 2003-07-24 2004-02-11 华东理工大学 重组 trail 包含体蛋白的工业化提取、复性和纯化方法

Also Published As

Publication number Publication date
JP2013060471A (ja) 2013-04-04
EP1888624B1 (de) 2011-06-22
US7741285B2 (en) 2010-06-22
US20060009387A1 (en) 2006-01-12
WO2006127284A3 (en) 2007-03-15
KR20080040637A (ko) 2008-05-08
MX2007014728A (es) 2008-02-15
CA2609188C (en) 2014-05-27
CN101228183A (zh) 2008-07-23
ZA200710325B (en) 2009-08-26
IL187396A0 (en) 2008-02-09
RU2007148007A (ru) 2009-06-27
IL187396A (en) 2012-08-30
CA2609188A1 (en) 2006-11-30
WO2006127284A2 (en) 2006-11-30
EP1888624A2 (de) 2008-02-20
AU2006249494B2 (en) 2011-09-15
CN101228183B (zh) 2012-06-06
ES2368445T3 (es) 2011-11-17
KR101283802B1 (ko) 2013-07-08
HK1113382A1 (en) 2008-10-03
BRPI0611368A2 (pt) 2010-08-31
AU2006249494A1 (en) 2006-11-30
JP2008542269A (ja) 2008-11-27
US20110054153A1 (en) 2011-03-03
NZ563518A (en) 2009-12-24
RU2435781C2 (ru) 2011-12-10

Similar Documents

Publication Publication Date Title
EP1669459A4 (de) Verfahren zur aufreinigung von bernsteinsäure aus fermentationsflüssigkeit
DE602006002843D1 (de) Verfahren und System zur Fahrzeugführung unter Berücksichtigung von Erntegut
DE112006003916A5 (de) Zwischenschaltkreis, Brennstoffzellensystem mit Zwischenschaltkreis sowie Verfahren zur Ansteuerung des Zwischenschaltkreises
DE502004008879D1 (de) Verfahren zur steuerung von energieströmen
DE602007013671D1 (de) System zur Verringerung von Kraftwerksemissionen
ATE486844T1 (de) Verfahren zur herstellung von adipodinitril durch hydrocyanierung von 1,3-butadien
DE602007011843D1 (de) Verfahren zur Herstellung von Gruppe-III-Nitridkristallen
ATE526017T1 (de) Abscheidung von polyelektrolyten und reinigung von antikörpern
EA200970300A1 (ru) Способ и устройство для опреснения
ATE544754T1 (de) Verfahren zur herstellung von ivabradinhydrochlorid
ATE408604T1 (de) Verfahren zur herstellung von 1-alkyl-3- phenyluracilen
IL185031A0 (en) Method for the preparation of pregabalin and salts thereof
DE602006015090D1 (de) Verfahren zur herstellung von gezielt durchlässigen laminaten
ATE544341T1 (de) Verfahren zur verbesserung des nematoden toleranten bzw. -resistenten pflanzenwachstums
ATE495286T1 (de) Verfahren zur hydrolyse von polyphosphorsäure in polyareneazolfasern
ATE554181T1 (de) Verfahren zur enantioselektiven enzymatischen reduktion von secodionderivaten unter kontinuierlicher cofaktor regenerierung
DE502004001216D1 (de) Verfahren zur aufreinigung von blausäure
ATE408616T1 (de) Verfahren zur aufreinigung von il-18-bindendem protein
DE502005010441D1 (de) Verfahren zur fertigung angepasster, strömungstechnischer oberflächen
EP1960416A4 (de) Verfahren zur aufreinigung von chenodesoxycholsäure
ATE394369T1 (de) Verfahren zur aufreinigung von mesotrion
ATE444303T1 (de) Verfahren zur herstellung von ferrisuccinylcasein
ATE406811T1 (de) Verfahren zur herstellung von brühe- oder würzewürfeln
ATE526302T1 (de) Verfahren zur aufreinigung von hexafluorpropendimeren
IL187396A0 (en) Apo-2 ligand/trail formulations

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1888624

Country of ref document: EP